Apr 5, 2017 • 8:30 am EDT Corbus Pharmaceuticals to Commence Single Phase 3 Study of Anabasum for Treatment of Systemic Sclerosis Following Guidance Received from Successful End-of-Phase 2 Meeting with FDA
Mar 30, 2017 • 6:00 am EDT Corbus Pharmaceuticals Reports Positive Topline Data Demonstrating Anabasum Reduces Acute Pulmonary Exacerbations and Multiple Inflammatory Biomarkers in Phase 2 Study in Patients with Cystic Fibrosis
Mar 9, 2017 • 7:00 am EST Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update
Mar 8, 2017 • 8:00 am EST Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways
Mar 1, 2017 • 7:30 am EST Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference
Feb 23, 2017 • 8:05 am EST Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients
Feb 21, 2017 • 7:30 am EST Corbus Pharmaceuticals to Host Research and Development Day on March 13, 2017
Jan 17, 2017 • 7:30 am EST Corbus Pharmaceuticals Receives Orphan Designation for JBT-101 for the Treatment of Systemic Sclerosis in the European Union